Health CarePharmaceuticals and Biotechnology
  • Price (EUR)1.20
  • Today's Change-0.006 / -0.50%
  • Shares traded4.11m
  • 1 Year change+76.20%
  • Beta0.9350
Data delayed at least 15 minutes, as of Dec 05 2022 16:35 GMT.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Pharming Group NV is a biopharmaceutical company based in the Netherlands. The Company is engaged in the development, production and commercialization of human therapeutic proteins to be used in the therapies. The Company's product portfolio is aimed at treatments for genetic disorders, blood-related disorders, infectious and inflammatory diseases, tissue and bone damage and surgical/traumatic bleeding. Its core product, RUCONEST (conestat alfa) is a recombinant human C1 esterase inhibitor approved for the treatment of acute Hereditary Angioedema (HAE) attacks in patients in Europe, the Unites States, Israel and South Korea. The product is available on a named-patient basis in other territories where it has not yet obtained marketing authorization.

  • Revenue in EUR (TTM)193.73m
  • Net income in EUR28.74m
  • Incorporated1988
  • Employees321.00
  • Location
    Pharming Group NVDarwinweg 24LEIDEN 2333 CRNetherlandsNLD
  • Phone+31 715247400
  • Fax+31 715247445
  • Websitehttps://www.pharming.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Avantium NV11.15m-29.84m162.97m213.00--1.25--14.62-0.8783-0.87830.32883.060.09451.810.513352,347.42-26.11-29.36-33.35-35.7478.9183.57-276.43-266.385.08-10.240.1809--10.690.7993-6.95--15.45--
Mithra Pharmaceuticals SA21.88m-93.23m230.11m248.00--5.85--10.52-2.11-2.110.49240.71420.05040.33230.889988,237.91-21.45-16.55-26.85-19.4233.4688.16-426.03-138.210.4207-7.010.859--151.030.1774-26.92--5.63--
Hyloris Pharmaceuticals SA3.29m-8.28m375.21m14.00--5.71--114.01-0.3162-0.31620.12592.350.0481--1.60238,478.30-12.09---13.52--96.17---251.63-----20.310.0011--1,669.14---62.06------
BenevolentAI SA-100.00bn-100.00bn568.44m----2.42----------1.65----------------------------0.0476--------------
Pharming Group N.V.194.60m28.87m781.96m321.0029.404.1216.654.020.04080.04080.27560.29160.52170.57996.63606,220.307.742.738.793.8791.6887.3614.844.394.68--0.41---6.2762.49-57.62--66.17--
Fagron NV625.79m69.41m914.60m3.06k13.182.469.131.460.95080.95088.575.100.71363.5010.55204,438.407.957.309.939.9842.1844.0511.1410.411.2314.060.527812.973.216.352.35--7.01--
Galapagos NV624.03m5.57m2.48bn1.36k90.010.920187.453.970.41780.417811.1040.860.1211--9.17476,719.600.108-2.450.121-2.7598.57--0.8918-17.828.34--0.0084--1.5728.8659.67--64.60--
Data as of Dec 05 2022. Currency figures normalised to Pharming Group NV's reporting currency: Euro EUR

Institutional shareholders

7.51%Per cent of shares held by top holders
HolderShares% Held
Acadian Asset Management LLCas of 01 Sep 202219.98m3.07%
BlackRock Fund Advisorsas of 03 Nov 202210.54m1.62%
Healthinvest Partners ABas of 30 Jun 20226.25m0.96%
Nordea Investment Management ABas of 30 Sep 20223.48m0.53%
Schroder Investment Management North America, Inc.as of 28 Feb 20212.96m0.45%
KBC Asset Management NVas of 30 Jun 20221.53m0.24%
BlackRock Advisors (UK) Ltd.as of 03 Nov 20221.13m0.17%
First Private Investment Management KAG mbHas of 29 Jul 20221.10m0.17%
Mandarine Gestion SAas of 29 Jul 20221.00m0.15%
NN Investment Partners Belgium SAas of 31 Dec 2021950.00k0.15%
More ▼
Data from 31 Mar 2022 - 30 Sep 2022Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.